Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 62Glioblastoma 52Lung Neoplasms 49Breast Neoplasms 46Prostatic Neoplasms 39Head and Neck Neoplasms 38Squamous Cell Carcinoma of Head and Neck 33Esophageal Neoplasms 30Brain Neoplasms 28Lymphoma 27Gliosarcoma 27Rectal Neoplasms 24Hodgkin Disease 24Pancreatic Neoplasms 22Adenocarcinoma Of Esophagus 22Central Nervous System Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Neoplasms 20Lymphoma, Non-Hodgkin 17Leukemia 17Glioma 17Burkitt Lymphoma 16Sarcoma 15Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Carcinoma, Squamous Cell 14Colorectal Neoplasms 13Astrocytoma 13Neoplasm Metastasis 12Melanoma 12

Interventions

Paclitaxel 2Carboplatin 2Bevacizumab 2Taxes 1Radiotherapy 1Nivolumab 1Immunoglobulin G 1Gemcitabine 1Erlotinib Hydrochloride 1Docetaxel 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma, Clear Cell × Radiotherapy × Clear all
NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 11 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡